Description

Retatrutide 12mg — Triple GLP-1/GIP/Glucagon Agonist

Retatrutide (LY3437943) by Eli Lilly simultaneously activates three metabolic receptors: GLP-1R (appetite suppression, insulin secretion), GIPR (energy metabolism, insulin sensitivity), and GCGR (thermogenesis, lipolysis). Phase 2 clinical data published in the NEJM (2023) demonstrated unprecedented 24.2% mean body weight reduction at 48 weeks — surpassing all previously reported pharmacological obesity treatments.

Research Applications

• Obesity, metabolic syndrome, and T2DM research
• NAFLD/NASH and hepatic fat accumulation studies
• Incretin axis pharmacology and GLP-1/GIP synergy research
• Thermogenesis and adipose tissue biology
• Cardiovascular metabolic risk factor studies

Specifications

• Retatrutide (LY3437943) | 12mg per vial | Purity: ≥98%
• Form: Lyophilized powder | Reconstitute with bacteriostatic water
• Storage: 2–8°C short-term, -20°C long-term

For research purposes only. Not for human consumption.